Antibiotic susceptibility of bacteria isolated from infections in cats and dogs throughout Europe (2002-2009)

Comp Immunol Microbiol Infect Dis. 2014 Mar;37(2):97-108. doi: 10.1016/j.cimid.2013.10.001. Epub 2013 Oct 14.

Abstract

A monitoring program of the pre-treatment susceptibility of clinical isolates of bacteria from diseased dogs and cats was active between the years 2002 and 2009. Susceptibility of each isolated strain to a panel of nine antibiotics (amoxicillin/clavulanic acid, ampicillin, penicillin, clindamycin, doxycycline, enrofloxacin, marbofloxacin, trimethoprim and trimethoprim/sulfamethoxazole) was assessed. The Minimum Inhibitory Concentration (MIC) of marbofloxacin was also determined by a standardized microdilution technique following CLSI recommendations. In total, 1857 bacterial strains were collected throughout Europe from cases of otitis, respiratory, urinary and dermatological infections. Although bacterial susceptibility varied for each of the antibiotics within the panel, patterns of susceptibility were similar to those described in the literature for comparable time periods and geographical areas. With a clinical resistance varying from 0 to 14.48% against the isolated strains, marbofloxacin susceptibility was very high and remains an effective antibiotic for the treatment of otitis, urinary, respiratory and dermatological infections in companion animals.

Keywords: Antimicrobial susceptibility; Cats; Dermatological infection; Dogs; Fluoroquinolone; Marbofloxacin; Otitis; Respiratory; Survey; Urinary.

MeSH terms

  • Animals
  • Anti-Bacterial Agents / pharmacology
  • Cat Diseases / drug therapy*
  • Cat Diseases / epidemiology
  • Cat Diseases / microbiology
  • Cats
  • Dog Diseases / drug therapy*
  • Dog Diseases / epidemiology
  • Dog Diseases / microbiology
  • Dogs
  • Drug Resistance, Multiple, Bacterial
  • Epidemiological Monitoring / veterinary
  • Europe / epidemiology
  • Fluoroquinolones / pharmacology
  • Gram-Negative Bacteria / drug effects
  • Gram-Negative Bacteria / growth & development
  • Gram-Negative Bacterial Infections / drug therapy
  • Gram-Negative Bacterial Infections / epidemiology
  • Gram-Negative Bacterial Infections / microbiology
  • Gram-Negative Bacterial Infections / veterinary*
  • Gram-Positive Bacteria / drug effects
  • Gram-Positive Bacteria / growth & development
  • Gram-Positive Bacterial Infections / drug therapy
  • Gram-Positive Bacterial Infections / epidemiology
  • Gram-Positive Bacterial Infections / microbiology
  • Gram-Positive Bacterial Infections / veterinary*
  • Microbial Sensitivity Tests
  • Otitis / drug therapy
  • Otitis / epidemiology
  • Otitis / microbiology
  • Otitis / veterinary
  • Respiratory Tract Infections / drug therapy
  • Respiratory Tract Infections / epidemiology
  • Respiratory Tract Infections / microbiology
  • Respiratory Tract Infections / veterinary
  • Skin Diseases, Bacterial / drug therapy
  • Skin Diseases, Bacterial / epidemiology
  • Skin Diseases, Bacterial / microbiology
  • Skin Diseases, Bacterial / veterinary
  • Treatment Outcome
  • Urinary Tract Infections / drug therapy
  • Urinary Tract Infections / epidemiology
  • Urinary Tract Infections / microbiology
  • Urinary Tract Infections / veterinary

Substances

  • Anti-Bacterial Agents
  • Fluoroquinolones
  • marbofloxacin